Abstract
Much progress in the medical therapy of chronic heart failure (HF) has been made in the last decades. The last was the introduction of a new treatment strategy based on the combination of the neprilysin inhibitor sacubitril and the angiotensin receptor blocker (ARB) valsartan into the pharmacological armamentarium, as reported in the PARADIGM-HF trial and its ancillary analyses. On the other hand, in the acute setting only scant progress in pharmacological treatments has been achieved, and most published data are based on observational studies or expert opinion. This review critically presents and discusses the most intriguing evidence from clinical trials in HF published in 2015. In particular, we focused on chronic HF with reduced ejection fraction and its comorbidities, while worsening HF or acute decompensated HF were more synthetically treated.
| Original language | English |
|---|---|
| Pages (from-to) | 1-9 |
| Number of pages | 9 |
| Journal | Expert Review of Cardiovascular Therapy |
| DOIs | |
| Publication status | Accepted/In press - Mar 16 2016 |
Fingerprint
Keywords
- clinical trials
- Heart failure
- LCZ696
- Pharmacological therapy
- serelaxin
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Internal Medicine
Cite this
Heart failure trials on pharmacological therapy in 2015 : lessons learned and future outlook. / Latini, Roberto; Masson, Serge; Staszewsky, Lidia.
In: Expert Review of Cardiovascular Therapy, 16.03.2016, p. 1-9.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Heart failure trials on pharmacological therapy in 2015
T2 - lessons learned and future outlook
AU - Latini, Roberto
AU - Masson, Serge
AU - Staszewsky, Lidia
PY - 2016/3/16
Y1 - 2016/3/16
N2 - Much progress in the medical therapy of chronic heart failure (HF) has been made in the last decades. The last was the introduction of a new treatment strategy based on the combination of the neprilysin inhibitor sacubitril and the angiotensin receptor blocker (ARB) valsartan into the pharmacological armamentarium, as reported in the PARADIGM-HF trial and its ancillary analyses. On the other hand, in the acute setting only scant progress in pharmacological treatments has been achieved, and most published data are based on observational studies or expert opinion. This review critically presents and discusses the most intriguing evidence from clinical trials in HF published in 2015. In particular, we focused on chronic HF with reduced ejection fraction and its comorbidities, while worsening HF or acute decompensated HF were more synthetically treated.
AB - Much progress in the medical therapy of chronic heart failure (HF) has been made in the last decades. The last was the introduction of a new treatment strategy based on the combination of the neprilysin inhibitor sacubitril and the angiotensin receptor blocker (ARB) valsartan into the pharmacological armamentarium, as reported in the PARADIGM-HF trial and its ancillary analyses. On the other hand, in the acute setting only scant progress in pharmacological treatments has been achieved, and most published data are based on observational studies or expert opinion. This review critically presents and discusses the most intriguing evidence from clinical trials in HF published in 2015. In particular, we focused on chronic HF with reduced ejection fraction and its comorbidities, while worsening HF or acute decompensated HF were more synthetically treated.
KW - clinical trials
KW - Heart failure
KW - LCZ696
KW - Pharmacological therapy
KW - serelaxin
UR - http://www.scopus.com/inward/record.url?scp=84962539379&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84962539379&partnerID=8YFLogxK
U2 - 10.1586/14779072.2016.1159957
DO - 10.1586/14779072.2016.1159957
M3 - Article
AN - SCOPUS:84962539379
SP - 1
EP - 9
JO - Expert Review of Cardiovascular Therapy
JF - Expert Review of Cardiovascular Therapy
SN - 1477-9072
ER -